Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Avon's FY 2010 Marred By "Execution Factors" In Key Markets

This article was originally published in The Rose Sheet

  • News

Executive Summary

For direct-seller Avon Products, fiscal 2010 was "a tale of two halves," with "executional" challenges in Brazil and Russia in the third and fourth quarters hampering sales and compromising operating margins, company execs indicated Feb. 8.

You may also be interested in...



Can Avon CEO McCoy Rise To “Superhuman” Task?

New CEO Sheri McCoy comes to Avon from Johnson & Johnson with a strong background in consumer products and a “significant turn-around track record,” according to Avon. However, “there is no cape flowing behind her,” notes Morningstar analyst Lauren DeSanto, speculating that Avon’s problems may require superhuman powers.

People In Brief

Avon Alters Management Lineup

People In Brief

Avon Alters Management Lineup

Table

View full table

Tags:
Latest Headlines

GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win

See All
UsernamePublicRestriction

Register

RS017433

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By